Product Name:
DNMT3A-pS105
Product Number:
ab-pn746
Target Full Name: DNA (cytosine-5)-methyltransferase 3A
Target Alias: DNA cytosine methyltransferase 3 alpha; DNA cytosine methyltransferase 3A2; DNA methyltransferase HsaIIIA; DNA MTase HsaIIIA; DNM3A; DNMT3A2; EC 2.1.1.37; M.HsaIIIA
Product Type Specific: DNMT3A phosphosite-specific antibody
Antibody Code: PN746
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S105
Protein UniProt: Q9Y6K1
Protein SigNET: DNMT3A
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human DNMT3A
Antibody Immunogen Sequence: EEG(pS)PAG(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues E102 to G108. The effect of S105 phosphorylation is unclear. This is the major in vivo phosphorylation site in DNMT3 (≥49 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). This human phosphosite is not conserved in vertebrates and may be restricted to humans.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse.
Related Product 1: DNMT1 expression antibody (Cat. No.: AB-NN241-1)
Related Product 2: DNMT1 expression antibody (Cat. No.: AB-NN241-2)
Related Product 3: DNMT1 expression antibody (Cat. No.: AB-NN241-3)
Related Product 4: DNMT3L expression antibody (Cat. No.: AB-NN242-1)
Scientific Background: DNMT3A (DNA (cytosine-5)-methyltransferase 3A) is a nuclear DNA methyltransferase that belongs to the class I-like SAM-binding methyltransferase superfamily, C5-methyltransferase family. It features a PWWP domain (targeting chromatin), an ADD domain (Zinc finger for protein interactions), and a C-terminal Methyltransferase (MTase) domain. DNMT3A is required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. It modifies DNA in a non-processive manner and also methylates non-CpG sites. It may preferentially methylate DNA linker between 2 nucleosomal cores and is inhibited by histone H1. It plays a role in paternal and maternal imprinting, and is required for methylation of most imprinted loci in germ cells. It acts as a transcriptional corepressor for ZBTB18. It is recruited to trimethylated 'Lys-36' of histone H3 (H3K36me3) sites. It can actively repress transcription through the recruitment of HDAC activity. It acts through two main forms: the long isoform DNMT3A1 (localized to heterochromatin) and the short isoform DNMT3A2 (associated with active euchromatin), with DNMT3A2 being predominant in embryonic stem cells. DNMT3A is highly expressed in fetal tissues, skeletal muscle, heart, peripheral blood mononuclear cells, kidney, and at lower levels in placenta, brain, liver, colon, spleen, small intestine and lung. DNMT3A is essential for normal development, and its dysregulation is a significant factor in cancer progression. Mutations in DNMT3A are frequently associated with hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), often leading to poor prognosis. This description may include information annotated by UniProt and/or Google AI.